Caboz 20 mg (Capsule)

Unit Price: ৳ 400.00 (3 x 10: ৳ 12,000.00)

Strip Price: ৳ 4,000.00

Medicine Details

Category	Details
Generic	Cabozantinib
Company	Beacon pharmaceuticals plc

Cabozantinib capsules are indicated for the treatment of advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC) in patients who have been previously treated with Sorafenib.
It inhibits the tyrosine kinase activity of various receptors, involved in normal cellular function and pathologic processes.
Recommended dosage is 60 mg once daily without food, with specific instructions for administration, dosing modifications, and pediatric use.
Contraindicated in patients with known hypersensitivity to Cabozantinib or its components.
Side effects may include hemorrhage, perforations and fistulas, thrombotic events, hypertension, diarrhea, palmar-plantar erythrodysesthesia, proteinuria, osteonecrosis of the jaw, wound complications, and reversible posterior leukoencephalopathy syndrome.
It can cause fetal harm, and effective contraception is advised for females of reproductive potential.
Storage conditions include keeping the capsules below 30°C in a cool and dry place.

Mode of action:
- Inhibition of various tyrosine kinase receptors including MET, VEGFR, AXL, RET, ROS1, and more
Absorption: Median time to peak concentration is 3 to 4 hours post-dose.
Distribution: Oral volume of distribution is approximately 319 L. Highly protein-bound in human plasma.
Elimination: Predicted terminal half-life is approximately 99 hours. Clearance at steady state is estimated to be 2.2 L/hr.
Metabolism: A substrate of CYP3A4 in vitro.
Excretion: Approximately 81% of the total administered radioactivity was recovered within a 48-day collection period.

Renal cell carcinoma: 60 mg once daily without food, until clinical benefit ends or unacceptable toxicity is experienced.
Hepatocellular carcinoma: 60 mg once daily without food, until disease progression or unacceptable toxicity.
Pediatric use: Safety and effectiveness in pediatric patients have not been established.
Additional instructions:
- Stop treatment at least 28 days prior to scheduled surgery
- Do not substitute capsules with tablets
- Administer at least 1 hour before or at least 2 hours after eating
- Swallow capsules whole, do not crush
- Do not take a missed dose within 12 hours of the next dose
- Dose modification for certain patients with hepatic impairment and those taking CYP450 inhibitors or inducers

With cyp3a4 inhibitors: Avoid coadministration to reduce risk of exposure-related adverse reactions
With cyp3a inducers: Avoid coadministration to maintain efficacy
Additional interaction:
- Avoid grapefruit or grapefruit juice
- Avoid St. John's Wort

Pregnancy: Can cause fetal harm, advise against use during pregnancy
Lactation: No information on presence in human milk, advise against breastfeeding during treatment and for 4 months after the final dose
Contraception: Effective contraception is advised for females of reproductive potential
Infertility: May impair fertility in females and males, based on findings in animals

Hemorrhage: Discontinue for severe hemorrhage
Perforations fistulas: Monitor for signs and symptoms, discontinue if appropriate management is not possible
Thrombotic events: Discontinue in case of serious thrombotic events
Hypertension crisis: Do not initiate in uncontrolled hypertension, monitor blood pressure regularly
Diarrhea: Withhold and resume at reduced dose based on severity
Palmar plantar erythrodysesthesia: Withhold and resume at reduced dose based on severity
Proteinuria: Monitor urine protein regularly, discontinue if nephrotic syndrome develops
Osteonecrosis of the jaw: Perform oral examination, withhold prior to dental surgery, advise for good oral hygiene practices
Wound complications: Stop at least 28 days prior to scheduled surgery, resume based on wound healing
Reversible posterior leukoencephalopathy syndrome: Evaluate in case of specific symptoms, discontinue if diagnosed
Embryo fetal toxicity: Can cause fetal harm, advise pregnant women and females of reproductive potential to use effective contraception

Reported case: One case of overdosage resulted in various symptoms including memory impairment, mental status changes, cognitive disturbance, weight loss, and increase in BUN.

Keep below 30°C in a cool and dry place, away from sunlight. Keep out of reach of children.